Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients

Jiménez, Begoña; Trigo, José; Pajares, Bella; Sáez, María Isabel Corbí; Quero, Cristina; Navarro, V.; Llácer, Casilda; Rodriguez, Laura Medina; Rueda, Antonio; Alba, Emilio

doi:10.1016/j.oraloncology.2012.09.003

Cited by 41 publications

(40 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of this study are relatively favorable when compared with other recent studies, which reported median OS of 9.1–10 months (12–14). Reasons for the longer response duration in this study may be that the other studies included patients who received PTX and Cmab as ≥2nd line chemotherapy for recurrence or metastatic disease, and who had had a previous treatment history with PTX, docetaxel (DTX), or Cmab.…”

Section: Discussionsupporting

confidence: 57%

“…As preclinical studies have shown that the combination of cetuximab (Cmab) and taxanes seems to be synergistic (10, 11), paclitaxel (PTX) plus Cmab is a palliative option after failure of platinum-based therapy, offering overall response rates (ORRs) of 38–55% and median OS of 7.6–10 months (12–14). Among others, Hitt et al prospectively showed that PTX and Cmab was active (ORR54%, median PFS 4.2months, median OS 8.1 months) as 1st line treatment in R/M HNSCC patients, for whom platinum is contraindicated (15).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck

et al. 2018

View full text Add to dashboard Cite

Purpose: We sought to evaluate the efficacy and safety of the combination of cetuximab (Cmab) and paclitaxel (PTX) in patients with squamous cell carcinoma of the head and neck (SCCHN) who had unresectable recurrent or metastatic (R/M) disease after platinum-based chemoradiotherapy.Materials and Methods: Data on 23 patients with SCCHN who received paclitaxel and cetuximab (Cmab) for R/M disease no more than 6 months after CRT completion were retrospectively reviewed. PTX and Cmab were given in a 28-day cycle (PTX, 80 mg/m2 on days 1, 8, and 15; Cmab, loading dose 400 mg/m2 followed by a weekly 250 mg/m2). The differences in prognosis between subgroups in different clinical settings were also assessed.Results: CRT had been delivered as definitive treatment in 13 cases (57%) and as adjuvant treatment in 10 (43%). Median time from CRT completion to disease recurrence or metastasis was 73 days (1–152). The best objective response and disease control rates were 52 and 83%, respectively, with 12 partial responses and seven cases of stable disease by Response Evaluation Criteria in Solid Tumors (RECIST). A total of 17 of 23 patients (74%) achieved a degree of tumor shrinkage. Median progression-free survival (PFS) and overall survival (OS) were 7.0 (95% confidence interval [CI]: 3.7–8.4) and 16.3 months (95% CI: 7.8–23.3), respectively. Patients with a longer duration (≥60 d) from CRT completion to disease progression had a statistically significantly longer OS than the others (median OS 22.3 vs. 8.1 months, log-rank test; p = 0.034). Main Grade 3 toxicities included neutropenia (13%), anemia (13%), and hypomagnesemia (13%). No Grade 4 toxicity or treatment-related death was seen.Conclusion: PTX and Cmab is a tolerable and effective option in SCCHN patients with symptomatic CRT-refractory disease. Its favorable effects on tumor shrinkage will help relieve tumor-associated symptoms.

show abstract

Section: Discussionsupporting

confidence: 57%

Section: Introductionmentioning

confidence: 99%

Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Some studies have been performed in the second line involving the continuation of cetuximab in platinum-refractory patients who have already received anti-EGFR antibodies. Promising data came from a Spanish study conducted by Jiménez et al [67] which reported the efficacy of the weekly paclitaxel and cetuximab combination. This second-line treatment was well tolerated and highly active in patients who experience disease progression after platinum-based CT, including those who present with resistant disease.…”

Section: Recurrent or Metastatic Hnsccmentioning

confidence: 99%

“…This second-line treatment was well tolerated and highly active in patients who experience disease progression after platinum-based CT, including those who present with resistant disease. However, this trial contained two biases: the small number of patients (only 22 were enrolled), and that they were cetuximab naïve [67]. The rationale of this recent study was confirmed by Hitt et al [68] who reported the efficacy of the addition of cetuximab to weekly paclitaxel in a phase II trial in the first-line treatment of patients with R/M-HNSCC.…”

Section: Recurrent or Metastatic Hnsccmentioning

confidence: 99%

State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013

Denaro¹,

Russi

Adamo

et al. 2014

Oncology

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cause of cancer death worldwide. Its treatment is complex and evolving. In general, early-stage disease may be managed with single-modality treatment while an advanced stage (about 60% of clinical presentation) needs a multidisciplinary approach. In this setting concurrent chemoradiation has been associated with improvement in locoregional control and organ preservation, but at the cost of significant acute and chronic toxicity. Molecular target therapies specially directed to epidermal growth factor receptor (EGFR) might improve the outcomes and reduce toxicities. In recurrent-metastatic (R/M) HNSCC, cetuximab, a monoclonal antibody against EGFR, plus platinum-based chemotherapy (CT) allow an overall survival (OS) of about 10 months. However, the prognosis for R/M-HNSCC remains dismal and additional efforts are needed. At the 2013 American Society of Clinical Oncology (ASCO) Meeting, data on induction CT, anti-EGFR inhibitors, innovative molecular targets and predictor factors were reported. Further results on target therapies were presented at the European Cancer Congress (ECC) 2013, where a large study also showed that hyperfractionated radiotherapy (RT) improve OS rates compared with standard RT. The aim of this review is to discuss current standards and emerging therapies by considering recent new updates.

show abstract

“…The most frequent grade 3 or 4 adverse events were neurotoxicity and skin rash in 17 and 12% of patients, respectively. Similarly, Jiménez et al [39] evaluated paclitaxel with weekly CTX in previously treated patients. Twenty-two patients received paclitaxel (80 mg/m 2 ) and CTX until progression or unacceptable toxicity.…”

Section: Resultsmentioning

confidence: 99%

Advanced Squamous Cell Carcinoma of the Head and Neck: The Current Role of Cetuximab

Granados-García

Aguilar-Ponce²,

Maldonado-Magos³

et al. 2016

ORL

View full text Add to dashboard Cite

We review clinical trials of squamous cell carcinoma of the head and neck (SCCHN) to address the current and potential uses of cetuximab (CTX). PubMed was reviewed to identify papers published between 2010 and 2016. The search terms used were “cetuximab” and “head and neck cancer.” A total of 634 articles were identified. Phase II or III studies with CTX in patients with advanced SCCHN without treatment or with recurrent/metastatic tumors were selected. Forty-six registries were obtained. Information was critically reviewed and relevant information presented. As definitive treatment of advanced squamous cells carcinomas and as palliative treatment of recurrent/metastatic disease, CTX alone or associated with chemotherapy and/or radiotherapy is an alternative to chemoradiotherapy because of its distinct and favorable toxicity profile.

show abstract

Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients

Cited by 41 publications

References 14 publications

Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck

Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck

State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013

Advanced Squamous Cell Carcinoma of the Head and Neck: The Current Role of Cetuximab

Contact Info

Product

Resources

About